Purchase of tablets by EuroPharma Alliance (Q95062): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The project is the implementation of a new technology line for advanced drafting and tablet in EuroPharma Alliance. It is intended to introduce innovative products in tablets and granules. The resulting products will be marked by parameters that are significantly better than those of competing products. The machinery purchased under the project will be of the highest quality. They will be made in a pharmaceutical standard and will have the nec...) |
(Created claim: summary (P836): The subject of the project is the implementation of a new technological line for advanced formulation and pilling at EuroPharma Alliance. It is intended to introduce innovative products in the form of tablets and granules. The resulting products will be characterised by parameters much better than competing products. The machines purchased as part of the project will be of the highest quality. They will be made as a pharmaceutical standard and w...) |
||||||||||||||
| Property / summary | |||||||||||||||
The subject of the project is the implementation of a new technological line for advanced formulation and pilling at EuroPharma Alliance. It is intended to introduce innovative products in the form of tablets and granules. The resulting products will be characterised by parameters much better than competing products. The machines purchased as part of the project will be of the highest quality. They will be made as a pharmaceutical standard and will have the necessary attestations to allow contact with food. Components and parts in contact with the product will be made of AISI 316 (or AISI 316L) steel. Surfaces having contact with the pharmaceutical product will be polished to Ra less than 0.8 µm. Non-material parts contacting the product should be made of silicone, EPDM or PTFE. Thanks to the purchase of 5 sets of machines, i.e. mixer-granulator with integrated tapered mill, fluid dryer with air preparation station, rotary tablet machine, coating coating accessories (mixer, dosing pump) and preparation of drying air, ball mill and employment of two people (creating one full-time job which will increase employment in the company) The applicant will introduce innovative: dietary supplements in the form of iron gastro-resistant tablets, slow-release dietary supplements with melisa and slow-release tablets with valerin, controlled-release tablets, glucosamine film-coated granules and magnesium salt granules characterised by rapid decay and release of magnesium ions. Innovative products created within the framework of the project will be addressed to indirect recipients – owners of private brands, which will offer products to final customers. (English) | |||||||||||||||
| Property / summary: The subject of the project is the implementation of a new technological line for advanced formulation and pilling at EuroPharma Alliance. It is intended to introduce innovative products in the form of tablets and granules. The resulting products will be characterised by parameters much better than competing products. The machines purchased as part of the project will be of the highest quality. They will be made as a pharmaceutical standard and will have the necessary attestations to allow contact with food. Components and parts in contact with the product will be made of AISI 316 (or AISI 316L) steel. Surfaces having contact with the pharmaceutical product will be polished to Ra less than 0.8 µm. Non-material parts contacting the product should be made of silicone, EPDM or PTFE. Thanks to the purchase of 5 sets of machines, i.e. mixer-granulator with integrated tapered mill, fluid dryer with air preparation station, rotary tablet machine, coating coating accessories (mixer, dosing pump) and preparation of drying air, ball mill and employment of two people (creating one full-time job which will increase employment in the company) The applicant will introduce innovative: dietary supplements in the form of iron gastro-resistant tablets, slow-release dietary supplements with melisa and slow-release tablets with valerin, controlled-release tablets, glucosamine film-coated granules and magnesium salt granules characterised by rapid decay and release of magnesium ions. Innovative products created within the framework of the project will be addressed to indirect recipients – owners of private brands, which will offer products to final customers. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The subject of the project is the implementation of a new technological line for advanced formulation and pilling at EuroPharma Alliance. It is intended to introduce innovative products in the form of tablets and granules. The resulting products will be characterised by parameters much better than competing products. The machines purchased as part of the project will be of the highest quality. They will be made as a pharmaceutical standard and will have the necessary attestations to allow contact with food. Components and parts in contact with the product will be made of AISI 316 (or AISI 316L) steel. Surfaces having contact with the pharmaceutical product will be polished to Ra less than 0.8 µm. Non-material parts contacting the product should be made of silicone, EPDM or PTFE. Thanks to the purchase of 5 sets of machines, i.e. mixer-granulator with integrated tapered mill, fluid dryer with air preparation station, rotary tablet machine, coating coating accessories (mixer, dosing pump) and preparation of drying air, ball mill and employment of two people (creating one full-time job which will increase employment in the company) The applicant will introduce innovative: dietary supplements in the form of iron gastro-resistant tablets, slow-release dietary supplements with melisa and slow-release tablets with valerin, controlled-release tablets, glucosamine film-coated granules and magnesium salt granules characterised by rapid decay and release of magnesium ions. Innovative products created within the framework of the project will be addressed to indirect recipients – owners of private brands, which will offer products to final customers. (English) / qualifier | |||||||||||||||
point in time: 15 October 2020
| |||||||||||||||
Revision as of 18:08, 15 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Purchase of tablets by EuroPharma Alliance |
Project in Poland financed by DG Regio |
Statements
1,479,527.63 zloty
0 references
3,699,744.0 zloty
0 references
39.99 percent
0 references
1 October 2016
0 references
31 January 2018
0 references
EUROPHARMA ALLIANCE SP. Z O.O.
0 references
50°58'48.4"N, 17°2'27.2"E
0 references
Przedmiotem projektu jest wdrożenie nowej linii technologicznej do zaawansowanej formulacji i tabletkowania w firmie EuroPharma Alliance. Ma ona posłużyć do wprowadzenia innowacyjnych produktów w postaci tabletek oraz granulatu. Powstałe produkty będą odznaczać się parametrami znacznie lepszymi od produktów konkurencyjnych. Zakupione w ramach projektu maszyny będą odznaczać się najwyższą jakością. Będą wykonane w standardzie farmaceutycznym i będą posiadały niezbędne atesty dopuszczające do kontaktu z żywnością. Elementy i części posiadające kontakt z produktem wykonane będą ze stali AISI 316 ( lub AISI 316L). Powierzchnie mające styk z produktem farmaceutycznym będą wypolerowane do Ra mniejsze 0,8 µm. Części nie materiałowe stykające się z produktem powinny być wykonane z silikonu, EPDM lub PTFE. Dzięki zakupowi 5 zestawów maszyn tj. mieszarko-granulator ze zintegrowanym młynkiem stożkowym, suszarnia fluidalna ze stacją przygotowania powietrza, tabletkarka rotacyjna, powlekarka wraz z osprzętem do przygotowania powłoki (mieszalnik, pompa dozująca) oraz przygotowaniem powietrza suszącego oraz młyn kulowy oraz zatrudnieniu dwóch osób (utworzenie jednego pełnego etatu co spowoduje przyrost zatrudnienia w firmie) Wnioskodawca do swojej oferty wprowadzi innowacyjne: suplementy diety w formie tabletek powlekanych dojelitowych z żelazem, suplementy diety w formie tabletek o spowolnionym uwalnianiu z melisą oraz tabletek o spowolnionym uwalnianiu z walerianą, tabletki o kontrolowanym uwalnianiu kofeiny, granulat powlekany z glukozaminą oraz granulat z solami magnezu charakteryzujący się szybkim rozpadem i uwalnianiem jonów magnezu. Innowacyjne produkty powstałe w ramach projektu kierowane będą do odbiorów pośrednich – właścicieli prywatnych marek, które oferować będą produkty odbiorcom końcowym. (Polish)
0 references
The subject of the project is the implementation of a new technological line for advanced formulation and pilling at EuroPharma Alliance. It is intended to introduce innovative products in the form of tablets and granules. The resulting products will be characterised by parameters much better than competing products. The machines purchased as part of the project will be of the highest quality. They will be made as a pharmaceutical standard and will have the necessary attestations to allow contact with food. Components and parts in contact with the product will be made of AISI 316 (or AISI 316L) steel. Surfaces having contact with the pharmaceutical product will be polished to Ra less than 0.8 µm. Non-material parts contacting the product should be made of silicone, EPDM or PTFE. Thanks to the purchase of 5 sets of machines, i.e. mixer-granulator with integrated tapered mill, fluid dryer with air preparation station, rotary tablet machine, coating coating accessories (mixer, dosing pump) and preparation of drying air, ball mill and employment of two people (creating one full-time job which will increase employment in the company) The applicant will introduce innovative: dietary supplements in the form of iron gastro-resistant tablets, slow-release dietary supplements with melisa and slow-release tablets with valerin, controlled-release tablets, glucosamine film-coated granules and magnesium salt granules characterised by rapid decay and release of magnesium ions. Innovative products created within the framework of the project will be addressed to indirect recipients – owners of private brands, which will offer products to final customers. (English)
15 October 2020
0 references
Identifiers
RPDS.01.05.01-02-0247/16
0 references